Adaptimmune Therapeutics plc

Replay of Investor Day Virtual Event now available

View Replay Learn More

< >

Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS

< >

Elliot Norry, Chief Medical Officer – SITC 2020 Surpass Presentation

Click Here

< >

Q3 2020 Business and Financial Update

Click Here

< >

We have been chosen as one of the Best Places to work in Philadelphia

Click Here

< >

Adaptimmune’s mission is to transform the lives of people with cancer by designing and delivering cell therapies

Learn More

< >

Our Clinical Trials

Advancing T-cell therapy through world-class expertise

Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.

View Our Clinical Trials

For Patients and Families

Helpful resources for patients and their families

Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.

View Our Resources

Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.

View Our Pipeline

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.

Learn More